ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
21 announcements with these filters
Dr. Agarwal's Eye Hospital Limited has completed its amalgamation with Dr. Agarwal's Health Care Limited, with the transaction valued at ₹711.21 Crore.
Dr. Agarwal's Eye Hospital announced the effectiveness of its Scheme of Amalgamation starting November 01, 2026, and fixed a record date for share allotment.
The company submitted its quarterly shareholding pattern as mandated by SEBI. The filing provides a breakdown of shareholdings among promoters and the public.
The NCLT Chennai Bench has sanctioned the Scheme of Amalgamation between Dr. Agarwal’s Eye Hospital Limited and Dr. Agarwal’s Health Care Limited. The company awaits the order copy.
Dr. Agarwal's Eye Hospital Limited held its 32nd Annual General Meeting on September 09, 2026. The meeting concluded with the approval of six business resolutions.
Dr. Agarwals Eye Hospital inaugurated its new Pinhole Pupilloplasty Centre in Chennai. This facility provides advanced specialized clinical treatments for patients with complex corneal conditions.
Dr. Agarwal’s Eye Hospital will hold its 32nd Annual General Meeting on September 09, 2026. The meeting includes approval for a final dividend of ₹4.00 per share.
Dr. Agarwal's Eye Hospital Limited has submitted its Annual Report for the financial year 2025-26, including the notice for its 32nd Annual General Meeting.
Invesco Mutual Fund acquired a 2.1885% stake in Dr. Agarwal's Healthcare Limited via open market. Its total holding in the company now stands at 5.2125%.
Dr. Agarwal's Eye Hospital Limited has re-appointed M/s. B Y & Associates as Cost Auditor for a one-year term.
Dr. Agarwal's Eye Hospital Ltd reported revenue from operations of ₹143 Cr (+22.3% YoY) and net profit of ₹23.4 Cr (+35.3% YoY) for Q1 FY27.
Dr. Agarwal's Eye Hospital Limited has scheduled a Board of Directors meeting on August 03, 2026, to consider and approve its unaudited quarterly financial results.
Dr. Agarwal's Eye Hospital Ltd. announced shareholder approval for its amalgamation with Dr. Agarwal's Health Care Ltd. The NCLT-convened meeting passed the scheme with 89.87% of votes polled in favor.
Dr. Agarwal's Eye Hospital held an NCLT-convened shareholder meeting to consider its amalgamation scheme. The meeting concluded after voting procedures were completed.
Dr. Agarwal's Eye Hospital Limited convened an NCLT-directed shareholder meeting on July 02, 2026. The meeting seeks approval for its proposed amalgamation with Dr. Agarwal's Health Care Limited.
Dr. Agarwal's Eye Hospital Ltd reported revenue from operations of ₹120 Cr (+20.2% YoY) and net profit of ₹16.2 Cr (+1.2% YoY) for Q4 FY26.
Dr. Agarwal's Eye Hospital reported a total income of ₹476.69 Crore for FY2026. The board also recommended a final dividend of ₹4 per equity share.
Dr. Agarwal’s Eye Hospital scheduled a board meeting for May 20, 2026. The board will consider audited annual results and a final dividend recommendation.
NCLT Chennai Bench directed Dr. Agarwal’s Eye Hospital to convene meetings for its amalgamation scheme on July 02, 2026. The merger remains subject to necessary statutory approvals.
Dr. Agarwal's Eye Hospital Limited announced that its equity shares were admitted to dealings on the NSE effective April 20, 2026, under the symbol DRAGARWQ. This is an exchange-led action and the company remains listed on the BSE. No formal listing application was filed by the company for this NSE trading admission.
Dr. Agarwal’s Eye Hospital Limited submitted its quarterly compliance certificate for the period ending March 31, 2026. The filing confirms the dematerialisation of share certificates and reconciliation of records with depositories as per SEBI regulations. This is a routine administrative disclosure with no direct financial impact.